RankAlpha logo
Back to Rankings

KYTX

Kyverna TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
KYTX has unusually near-dated biotech catalysts: dual AAN presentations in April 2026, a stated SPS BLA target in 1H 2026, and cash runway management says extends into 2028 while funding SPS launch prep and Phase 3 gMG execution [#8-K-2026-03-26] [#10-K-2026-03-26].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +10.2.
What can break
Cash runway is guided into 2028, but burn remains high and future dilution risk is not eliminated if timelines extend or commercialization costs rise [#8-K-2026-03-26] [#10-K-2026-03-26].
Momentum
65
Value
41
Sentiment
81
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $10.50 · Bull $16.00 · Bear $5.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $29.60
Why
Momentum65 · Δ7d -13.5
Value41 · Δ7d +0.1
Sentiment81 · Δ7d +10.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
65
34% active weight
Current posture
7d trendSoftening
Δ7d
-13.5
Δ21d
-13.4
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
81
33% active weight
Current posture
7d trendImproving
Δ7d
+10.2
Δ21d
+34.8
Why this grade

Composite grade A. Momentum 64.5 / Value 41.1 / Sentiment 80.7

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$499.74M
Beta
-
Shares Out
57.13M
P/E (TTM) · Derived
-2.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.39
Rev YoY
-
EPS YoY
-6.0%
Gross Margin
-
Op Margin
-
Net Debt
-$285.06M
Current Ratio
5.16
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology